Supplementary Figures 1-11, Tables 1-2 from MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition
PDF file - 1MB, Figure S1. Overexpression of miR-183-96-182 cluster miRNAs in U2OS cells. Figure S2. Effects of miR-183-96-182 cluster miRNAs on cisplatin-induced foci formation of RAD51, RPA2, FANCD2 and BRCA1. Figure S3. Overexpression of miR-96 sensitizes cancer cells to cisplatin and AZD2281. Figure S4. Overexpression of miR-96 sensitizes HR-deficient cancer cells to cisplatin. Figure S5. MiR-96 is highly conserved across species. Figure S6. Conservation of miR-96 binding sites and surrounding regions in the transcripts of REV1 and RAD51. Figure S7. Combinational treatment with miR-96 and cisplatin delayed tumor growth. Figure S8. Effects of miR-183-96-182 cluster miRNA mimics on cellular sensitivity to cisplatin and AZD2281. Figure S9. Effects of IR on the expression of miR-183-96-182 cluster miRNAs. Figure S10. Effect of miR-183-96-182 cluster miRNAs on BRCA1 and REV1 expression. Figure S11. Effect of miR-183-96-182 cluster miRNAs on cell growth. Supplementary Tables S1-S2 Table S1. Top 100 predicted targets of miR-96 by each miRNA prediction algorithm. Table S2. Predicted miR-96 targets by at least two prediction algorithms